Advertisement

United Therapeutics Corporation UTHR

Set alert

Price alert · UTHR

All alert types
598.72 USD +5.18 +0.87%

At close · Oct 30

598.72 0.00 0.00%

After hours · Oct 30, 6:34 PM ET

Bid
598.41 × 1
Ask
599.04 × 1
593.57 Day range 609.99
437.33 52-week range 598.72
YTD
+22.88%
1 year
+32.01%
Open
600.00
Prev close
593.54
Mkt cap
25.68B
Vol
518.24K
Avg vol
717.53K
EPS
27.92
P/E
21.44
Div yield
0.00%
More statistics
Low
593.57
High
609.99
Forward P/E
17.67
Beta
0.49
Short ratio
2.42
Inst. own
100.39%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
525.55
200-d avg
530.92
1y target
670.93

MAX chart

Chart tools
Interval

Events in this range
  • May 6, 2026Earnings: 5.82; estimate 7; surprise -16.86%
  • Aug 5, 2026Earnings: 7.27; estimate 6.86; surprise 5.98%
  • Oct 1, 2026Rating: BTIG · Neutral → Buy
  • Oct 7, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
  • Nov 4, 2026Earnings: —; estimate 6.01; surprise —%
Signals (113)
NameDateAgo
RSI: OverboughtOct 1, 20261 month ago
SMA: BullishSep 1, 20262 months ago
SMA: BearishAug 1, 20263 months ago
MACD: Buy SignalOct 1, 20251 year ago
RSI: OverboughtOct 1, 20251 year ago
SMA: BullishSep 1, 20251 year ago
SMA: BullishAug 1, 20251 year ago
SMA: BearishJul 1, 20251 year ago
MACD: Sell SignalApr 1, 20251 year ago
SMA: BearishFeb 1, 20251 year ago
RSI: OverboughtAug 1, 20242 years ago
MACD: Buy SignalJun 1, 20242 years ago
RSI: OverboughtJun 1, 20242 years ago
SMA: BullishFeb 1, 20242 years ago
SMA: BullishFeb 1, 20242 years ago
SMA: BearishJan 1, 20242 years ago
SMA: BearishDec 1, 20232 years ago
SMA: BullishNov 1, 20233 years ago
SMA: BearishAug 1, 20233 years ago
SMA: BullishJul 1, 20233 years ago
SMA: BearishMar 1, 20233 years ago
MACD: Sell SignalMar 1, 20233 years ago
MACD: Buy SignalJun 1, 20224 years ago
SMA: BullishMay 1, 20224 years ago
SMA: BearishFeb 1, 20224 years ago
MACD: Sell SignalFeb 1, 20224 years ago
RSI: OverboughtAug 1, 20215 years ago
RSI: OverboughtApr 1, 20215 years ago
SMA: BullishOct 1, 20206 years ago
SMA: BullishOct 1, 20206 years ago
SMA: BearishSep 1, 20206 years ago
SMA: BearishSep 1, 20206 years ago
SMA: BullishApr 1, 20206 years ago
MACD: Buy SignalFeb 1, 20206 years ago
SMA: BullishJan 1, 20206 years ago
MACD: Sell SignalApr 1, 20197 years ago
SMA: BearishMar 1, 20197 years ago
SMA: BearishMar 1, 20197 years ago
SMA: BullishFeb 1, 20197 years ago
SMA: BullishFeb 1, 20197 years ago
MACD: Buy SignalFeb 1, 20197 years ago
SMA: BearishDec 1, 20187 years ago
SMA: BullishNov 1, 20188 years ago
SMA: BearishOct 1, 20188 years ago
SMA: BearishOct 1, 20188 years ago
SMA: BullishSep 1, 20188 years ago
SMA: BullishJul 1, 20188 years ago
SMA: BearishFeb 1, 20188 years ago
SMA: BearishJan 1, 20188 years ago
MACD: Sell SignalJan 1, 20188 years ago
SMA: BullishDec 1, 20178 years ago
MACD: Buy SignalDec 1, 20178 years ago
SMA: BullishNov 1, 20179 years ago
MACD: Sell SignalMay 1, 20179 years ago
SMA: BearishApr 1, 20179 years ago
SMA: BearishMar 1, 20179 years ago
MACD: Buy SignalJan 1, 20179 years ago
SMA: BullishDec 1, 20169 years ago
SMA: BullishOct 1, 201610 years ago
SMA: BearishJan 1, 201610 years ago
MACD: Sell SignalSep 1, 201511 years ago
SMA: BearishAug 1, 201511 years ago
RSI: OverboughtSep 1, 201412 years ago
SMA: BullishAug 1, 201412 years ago
MACD: Buy SignalAug 1, 201412 years ago
MACD: Sell SignalJul 1, 201412 years ago
SMA: BearishJun 1, 201412 years ago
RSI: OverboughtOct 1, 201313 years ago
SMA: BullishDec 1, 201213 years ago
SMA: BullishNov 1, 201214 years ago
SMA: BearishOct 1, 201214 years ago
SMA: BearishOct 1, 201214 years ago
MACD: Buy SignalAug 1, 201214 years ago
SMA: BullishJul 1, 201214 years ago
SMA: BullishJun 1, 201214 years ago
SMA: BearishApr 1, 201214 years ago
SMA: BullishMar 1, 201214 years ago
SMA: BearishAug 1, 201115 years ago
SMA: BearishJun 1, 201115 years ago
MACD: Sell SignalJun 1, 201115 years ago
MACD: Buy SignalOct 1, 201016 years ago
SMA: BullishSep 1, 201016 years ago
MACD: Sell SignalJul 1, 201016 years ago
SMA: BearishMay 1, 201016 years ago
MACD: Buy SignalAug 1, 200917 years ago
SMA: BullishMay 1, 200917 years ago
SMA: BullishMay 1, 200917 years ago
SMA: BearishNov 1, 200818 years ago
MACD: Sell SignalNov 1, 200818 years ago
SMA: BearishOct 1, 200818 years ago
RSI: OverboughtJul 1, 200818 years ago
RSI: OverboughtNov 1, 200719 years ago
MACD: Buy SignalJul 1, 200719 years ago
SMA: BullishMay 1, 200719 years ago
SMA: BullishApr 1, 200719 years ago
SMA: BearishMar 1, 200719 years ago
SMA: BearishMar 1, 200719 years ago
SMA: BullishFeb 1, 200719 years ago
SMA: BullishFeb 1, 200719 years ago
SMA: BearishJan 1, 200719 years ago
SMA: BearishDec 1, 200619 years ago
SMA: BullishOct 1, 200620 years ago
SMA: BearishApr 1, 200620 years ago
MACD: Sell SignalApr 1, 200620 years ago
SMA: BullishMar 1, 200620 years ago
SMA: BearishFeb 1, 200620 years ago
RSI: OverboughtFeb 1, 200521 years ago
RSI: OverboughtNov 1, 200422 years ago
SMA: BullishDec 1, 200322 years ago
SMA: BearishNov 1, 200323 years ago
SMA: BullishMar 1, 200323 years ago
SMA: BullishFeb 1, 200224 years ago
SMA: BearishOct 1, 200026 years ago

Key statistics

Market cap
25.68B
Enterprise value
22.80B
Trailing P/E
21.44
Forward P/E
17.67
PEG ratio
2.22
Price / sales
8.14
Price / book
3.99
EPS (TTM)
27.92
Beta
0.49
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
41.56%
Revenue (TTM)
3.15B
Revenue growth
-1.90%
Free cash flow
557.14M
Total cash
2.66B
Total debt
0
Return on equity
19.31%
Shares outstanding
42.89M
Short % of float
6.69%
50-day average
525.55
200-day average
530.92

Analyst view

Consensus: buy

Buy
Price target (mean) 670.93 +12.1% upside
Target (low)
368.00
Target (mean)
670.93
Target (high)
850.00
Ratings (0m) 15 11 buy · 3 hold · 1 sell
  • Strong buy3
  • Buy8
  • Hold3
  • Sell1
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 6.34.

Earnings history

Financials — quick view

All financials
UTHR Revenue — quarterly 783.30M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
UTHR Net income — quarterly 333.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
UTHR EPS — quarterly 7.82
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

UTHR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20266.01———
Aug 5, 2026Jun 30, 20266.867.27+0.41+5.98%
May 6, 2026Mar 31, 20267.005.82-1.18-16.86%
Feb 25, 2026Dec 31, 20257.137.70+0.57+7.99%
Oct 29, 2025Sep 30, 20256.897.16+0.27+3.92%
Jul 30, 2025Jun 30, 20257.296.41-0.88-12.07%

Upgrades / downgrades

UTHR analyst upgrades and downgrades
DateFirmActionFromTo
Oct 28, 2026JP MorganmainOverweightOverweight
Oct 22, 2026RBC CapitalmainOutperformOutperform
Oct 19, 2026Leerink PartnersmainOutperformOutperform
Oct 8, 2026RBC CapitalmainOutperformOutperform
Oct 7, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 1, 2026BTIGupNeutralBuy

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
unither.com

News

Your note

Sign in to keep a note on UTHR — it syncs with the Stock Master app.

Insider holders

UTHR insider holders
InsiderRelationLatest transactionDateShares held
BENKOWITZ MICHAELPresidentConversion of Exercise of derivative securityMar 12, 20260
CAUSEY CHRISTOPHERDirectorSaleMar 29, 20264,190
EDGEMOND JAMES C.Chief Financial OfficerSaleJun 21, 202618,876
GILTNER RICHARD ADirectorConversion of Exercise of derivative securityJul 8, 202621,884
KURZWEIL RAYMOND CDirectorConversion of Exercise of derivative securityJul 8, 202613,320
MAHON PAUL AGeneral CounselSaleSep 30, 202645,172

Institution ownership

UTHR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.34%5,294,5293.17BJun 29, 2026
Avoro Capital Advisors LLC6.48%2,777,7771.66BJun 29, 2026
Vanguard Portfolio Management LLC4.48%1,919,4291.15BJun 29, 2026
Vanguard Capital Management LLC4.47%1,918,2561.15BJun 29, 2026
State Street Corporation4.43%1,898,0641.14BJun 29, 2026
Renaissance Technologies, LLC3.98%1,708,7391.02BJun 29, 2026

Fund ownership

UTHR fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,527,799914.72MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.14%1,347,720806.91MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.27%973,490582.85MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.68%719,385430.71MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.13%486,555291.31MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.75%323,432193.65MSep 29, 2026
Advertisement